Evidence map›Paper›PMID 41246357›Full record

ArticleFrontiers in immunology2025

Microbiota-immune dysregulation in cervical cancer patients from Western Mexico: linking gut dysbiosis and NK cell exhaustion as promising biomarkers.

Ksenia Klimov-Kravtchenko, Tonatiuh Abimael Baltazar-Díaz, Jesse Haramati, Paula Alejandra Castaño-Jiménez, Fabiola Solorzano-Ibarra, Jose Manuel Rojas-Diaz, Nadia Tatiana Garcia-Barrientos, Jose Alfonso Cruz-Ramos, Carmen Gahia Facundo-Medina, Susana Del Toro-Arreola and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ksenia Klimov-KravtchenkoDepartamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Tonatiuh Abimael Baltazar-DíazDepartamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Jesse HaramatiLaboratorio de Inmunología Traslacional, Departamento de Biología Celular y Molecular, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Zapopan, Jalisco, Mexico.
Paula Alejandra Castaño-JiménezDepartamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Fabiola Solorzano-IbarraDepartamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Jose Manuel Rojas-DiazDepartamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Nadia Tatiana Garcia-BarrientosDepartamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Jose Alfonso Cruz-RamosCoordinación de Investigación, Subdirección de Desarrollo Institucional, Instituto Jalisciense de Cancerología, Guadalajara, Jalisco, Mexico.
Carmen Gahia Facundo-MedinaCoordinación de Investigación, Subdirección de Desarrollo Institucional, Instituto Jalisciense de Cancerología, Guadalajara, Jalisco, Mexico.
Susana Del Toro-Arreola *Departamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Miriam Ruth Bueno-Topete *Departamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations in gut microbiota composition have been implicated in various diseases, including cancer. Recent evidence suggests that intestinal microbiota may influence the efficacy of immunotherapy. In this study, we investigated the relationship between gut dysbiosis and NK cell exhaustion in Mexican patients with cervical cancer (CC), a connection not previously explored. This cross-sectional study included newly diagnosed CC patients, a separate cohort of post-radio-chemotherapy (RCT) patients, and healthy donors (HD). Fecal microbiota profiles were assessed using 16S rRNA sequencing, while peripheral NK cell immune checkpoint expression was analyzed by multiparametric flow cytometry. CC patients exhibited significant gut dysbiosis, marked by reduced α-diversity, enrichment of pro-inflammatory taxa (

Indexed as

DysbiosisGastrointestinal MicrobiomeKiller Cells, NaturalUterine Cervical NeoplasmsAdultAgedBiomarkers, TumorCross-Sectional StudiesFemaleHumansImmune System ExhaustionMexicoMiddle AgedRNA, Ribosomal, 16SBiomarkers, TumorRNA, Ribosomal, 16Scervical cancerdysbiosisgut microbiotaimmune checkpointsimmune exhaustionNK cell

Identifiers

PMID41246357
PMCPMC12615445

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.